Zoetis Inc. stands out in the animal health industry with a robust portfolio spanning medicinal and diagnostic products for both livestock and companion animals. Their strategic positioning in the healthcare sector promises stable growth opportunities. However, investors should weigh its medium-term volatility against long-term potential.
The fundamental analysis of Zoetis showcases strong financial metrics, with notable strength in return metrics while facing challenges with its pricing multiples.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 2 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
The following table reveals consistency in Zoetis's financial performance, with negligible variations over the tracked period.
| Date | Overall Score | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-11-05 | 3 | 4 | 5 | 5 | 2 | 2 | 1 |
| Previous | 0 | 4 | 5 | 5 | 2 | 2 | 1 |
Analyst consensus illustrates a favorable view on Zoetis with a "Buy" recommendation driven by promising price targets.
| High | Low | Median | Consensus |
|---|---|---|---|
| $215 | $140 | $158 | $171 |
The prevailing sentiment among analysts leans strongly towards purchase recommendations for Zoetis stock.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 16 | |
| Hold | 13 | |
| Sell | 0 | |
| Strong Sell | 0 |
Zoetis Inc. exhibits a commendable balance between growth prospects and financial health, appealing to investors seeking exposure in the animal healthcare domain. With a favorable analyst consensus and competitive market standing, it is likely to sustain growth, albeit potential barriers such as market volatility and industry competition. Long-term investors might find appealing value in its strategic thrust, despite short-term unpredictabilities linked to economic cycles.